Nabla Bio

Nabla Bio is a biotechnology company that uses generative AI to design drugs, with a focus on antibodies and other biologics. Its goal is to make drug development a design discipline and reduce trial and error. The company is based in Cambridge, Massachusetts, and works fully in person. The core technology is JAM, a multimodal generative model trained on large volumes of protein sequence and structure data and strengthened with human relevant measurements produced in Nabla's own labs. JAM can take partial molecular context, such as a disease target or epitope, and complete the rest. The company describes uses including de novo antibody design, epitope scaffolding, affinity and developability optimization, and multispecific formats. Because JAM specifies the binding epitope up front, many design campaigns can run in parallel against different sites on a target. Nabla pairs the model with an integrated wet lab that tests thousands of designs for binding, developability and function in cellular and in vivo settings. The most recent announcement is JAM 2, aimed at drug like antibodies designed directly on the computer, with a technical report available. The company works through partnerships with pharmaceutical companies, who engage Nabla to design drugs against their targets. It is not a self serve software tool. Pricing is not published, and business inquiries go through a partner contact on the site.